HDAC1,2 Knock-Out and HDACi Induced Cell Apoptosis in Imatinib-Resistant K562 Cells

Since imatinib (Glivec or Gleevec) has been used to target the BCR-ABL fusion protein, chronic myeloid leukemia (CML) has become a manageable chronic disease with long-term survival. However, 15%–20% of CML patients ultimately develop resistance to imatinib and then progress to an accelerated phase...

Descripción completa

Detalles Bibliográficos
Autores principales: Chen, Shu-Huey, Chow, Jyh-Ming, Hsieh, Yao-Yu, Lin, Chun-Yu, Hsu, Kai-Wen, Hsieh, Wen-Shyang, Chi, Wei-Ming, Shabangu, Beished M., Lee, Chia-Hwa
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2019
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6539538/
https://www.ncbi.nlm.nih.gov/pubmed/31071955
http://dx.doi.org/10.3390/ijms20092271

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6539538/
https://www.ncbi.nlm.nih.gov/pubmed/31071955
http://dx.doi.org/10.3390/ijms20092271

Ejemplares similares